1
|
Grosu ȘA, Chirilă M, Rad F, Enache A, Handra CM, Ghiță I. The Effects of Four Compounds That Act on the Dopaminergic and Serotonergic Systems on Working Memory in Animal Studies; A Literature Review. Brain Sci 2023; 13:brainsci13040546. [PMID: 37190512 DOI: 10.3390/brainsci13040546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 03/23/2023] [Accepted: 03/23/2023] [Indexed: 03/29/2023] Open
Abstract
The dopaminergic and serotonergic systems are two of the most important neuronal pathways in the human brain. Almost all psychotropic medications impact at least one neurotransmitter system. As a result, investigating how they affect memory could yield valuable insights into potential therapeutic applications or unanticipated side effects. The aim of this literature review was to collect literature data from animal studies regarding the effects on memory of four drugs known to act on the serotonergic and dopaminergic systems. The studies included in this review were identified in the PubMed database using selection criteria from the PRISMA protocol. We analyzed 29 articles investigating one of four different dopaminergic or serotonergic compounds. Studies conducted on bromocriptine have shown that stimulating D2 receptors may enhance working memory in rodents, whereas inhibiting these receptors could have the opposite effect, reducing working memory performance. The effects of serotonin on working memory are not clearly established as studies on fluoxetine and ketanserin have yielded conflicting results. Further studies with better-designed methodologies are necessary to explore the impact of compounds that affect both the dopaminergic and serotonergic systems on working memory.
Collapse
|
2
|
Lista S, Vergallo A, Teipel SJ, Lemercier P, Giorgi FS, Gabelle A, Garaci F, Mercuri NB, Babiloni C, Gaire BP, Koronyo Y, Koronyo-Hamaoui M, Hampel H, Nisticò R. Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases. Ageing Res Rev 2023; 84:101819. [PMID: 36526257 DOI: 10.1016/j.arr.2022.101819] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 11/11/2022] [Accepted: 12/09/2022] [Indexed: 12/14/2022]
Abstract
Acetylcholinesterase inhibitors (ChEI) are the global standard of care for the symptomatic treatment of Alzheimer's disease (AD) and show significant positive effects in neurodegenerative diseases with cognitive and behavioral symptoms. Although experimental and large-scale clinical evidence indicates the potential long-term efficacy of ChEI, primary outcomes are generally heterogeneous across outpatient clinics and regional healthcare systems. Sub-optimal dosing or slow tapering, heterogeneous guidelines about the timing for therapy initiation (prodromal versus dementia stages), healthcare providers' ambivalence to treatment, lack of disease awareness, delayed medical consultation, prescription of ChEI in non-AD cognitive disorders, contribute to the negative outcomes. We present an evidence-based overview of determinants, spanning genetic, molecular, and large-scale networks, involved in the response to ChEI in patients with AD and other neurodegenerative diseases. A comprehensive understanding of cerebral and retinal cholinergic system dysfunctions along with ChEI response predictors in AD is crucial since disease-modifying therapies will frequently be prescribed in combination with ChEI. Therapeutic algorithms tailored to genetic, biological, clinical (endo)phenotypes, and disease stages will help leverage inter-drug synergy and attain optimal combined response outcomes, in line with the precision medicine model.
Collapse
Affiliation(s)
- Simone Lista
- Memory Resources and Research Center (CMRR), Neurology Department, Gui de Chauliac University Hospital, Montpellier, France; School of Pharmacy, University of Rome "Tor Vergata", Rome, Italy.
| | - Andrea Vergallo
- Sorbonne University, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - Stefan J Teipel
- German Center for Neurodegenerative Diseases (DZNE) Rostock/Greifswald, Rostock, Germany; Department of Psychosomatic Medicine and Psychotherapy, University Medicine Rostock, Rostock, Germany
| | - Pablo Lemercier
- Sorbonne University, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - Filippo Sean Giorgi
- Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy
| | - Audrey Gabelle
- Memory Resources and Research Center (CMRR), Neurology Department, Gui de Chauliac University Hospital, Montpellier, France
| | - Francesco Garaci
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy; Casa di Cura "San Raffaele Cassino", Cassino, Italy
| | - Nicola B Mercuri
- Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; IRCCS Santa Lucia Foundation, Rome, Italy
| | - Claudio Babiloni
- Department of Physiology and Pharmacology "Erspamer", Sapienza University of Rome, Rome, Italy; Hospital San Raffaele Cassino, Cassino, Italy
| | - Bhakta Prasad Gaire
- Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Yosef Koronyo
- Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Maya Koronyo-Hamaoui
- Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Biomedical Sciences, Division of Applied Cell Biology and Physiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Harald Hampel
- Sorbonne University, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - Robert Nisticò
- School of Pharmacy, University of Rome "Tor Vergata", Rome, Italy; Laboratory of Pharmacology of Synaptic Plasticity, EBRI Rita Levi-Montalcini Foundation, Rome, Italy.
| |
Collapse
|
3
|
Brzdak P, Wójcicka O, Zareba-Koziol M, Minge D, Henneberger C, Wlodarczyk J, Mozrzymas JW, Wójtowicz T. Synaptic Potentiation at Basal and Apical Dendrites of Hippocampal Pyramidal Neurons Involves Activation of a Distinct Set of Extracellular and Intracellular Molecular Cues. Cereb Cortex 2020; 29:283-304. [PMID: 29228131 DOI: 10.1093/cercor/bhx324] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Accepted: 11/07/2017] [Indexed: 12/12/2022] Open
Abstract
In the central nervous system, several forms of experience-dependent plasticity, learning and memory require the activity-dependent control of synaptic efficacy. Despite substantial progress in describing synaptic plasticity, mechanisms related to heterogeneity of synaptic functions at local circuits remain elusive. Here we studied the functional and molecular aspects of hippocampal circuit plasticity by analyzing excitatory synapses at basal and apical dendrites of mouse hippocampal pyramidal cells (CA1 region) in acute brain slices. In the past decade, activity of metalloproteinases (MMPs) has been implicated as a widespread and critical factor in plasticity mechanisms at various projections in the CNS. However, in the present study we discovered that in striking contrast to apical dendrites, synapses located within basal dendrites undergo MMP-independent synaptic potentiation. We demonstrate that synapse-specific molecular pathway allowing MMPs to rapidly upregulate function of NMDARs in stratum radiatum involved protease activated receptor 1 and intracellular kinases and GTPases activity. In contrast, MMP-independent scaling of synaptic strength in stratum oriens involved dopamine D1/D5 receptors and Src kinases. Results of this study reveal that 2 neighboring synaptic systems differ significantly in extracellular and intracellular cascades that control synaptic gain and provide long-searched transduction pathways relevant for MMP-dependent synaptic plasticity.
Collapse
Affiliation(s)
- Patrycja Brzdak
- Laboratory of Neuroscience, Department of Biophysics, Wroclaw Medical University, Wroclaw, Poland.,Department of Molecular Physiology and Neurobiology, Wroclaw University, Wroclaw, Poland
| | - Olga Wójcicka
- Laboratory of Neuroscience, Department of Biophysics, Wroclaw Medical University, Wroclaw, Poland
| | - Monika Zareba-Koziol
- Laboratory of Cell Biophysics, Department of Molecular and Cellular Neurobiology, Nencki Institute of Experimental Biology of Polish Academy of Sciences, Warsaw, Poland
| | - Daniel Minge
- Institute of Cellular Neurosciences, University of Bonn Medical School, Bonn, Germany
| | - Christian Henneberger
- Institute of Cellular Neurosciences, University of Bonn Medical School, Bonn, Germany.,Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Institute of Neurology, University College London, London, UK
| | - Jakub Wlodarczyk
- Laboratory of Cell Biophysics, Department of Molecular and Cellular Neurobiology, Nencki Institute of Experimental Biology of Polish Academy of Sciences, Warsaw, Poland
| | - Jerzy W Mozrzymas
- Laboratory of Neuroscience, Department of Biophysics, Wroclaw Medical University, Wroclaw, Poland.,Department of Molecular Physiology and Neurobiology, Wroclaw University, Wroclaw, Poland
| | - Tomasz Wójtowicz
- Laboratory of Neuroscience, Department of Biophysics, Wroclaw Medical University, Wroclaw, Poland
| |
Collapse
|
4
|
Esmaiel NN, Ashaat EA, Mosaad R, Fayez A, Ibrahim M, Abdallah ZY, Issa MY, Salem S, Ramadan A, El Wakeel MA, Ashaat NA, Zaki MS, Ismail S. The potential impact of COMT gene variants on dopamine regulation and phenotypic traits of ASD patients. Behav Brain Res 2019; 378:112272. [PMID: 31586564 DOI: 10.1016/j.bbr.2019.112272] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2019] [Revised: 08/27/2019] [Accepted: 10/01/2019] [Indexed: 01/04/2023]
Abstract
Catechol-O-methyltransferase (COMT) enzyme has a major role in the adjustment of catechol-dependent functions, for example, cognition, cardiac function, and pain processing. The pathogenesis of autism may be related to dysfunction in the midbrain dopaminergic system. Therefore, we aimed to clarify how COMT gene variants affect dopamine level, and its potential impact on phenotype traits of autistic patients. 52 autistic patients were subjected to comprehensive clinical investigation, sequencing of exon 4 of the COMT gene by direct Sanger Sequencing, and measuring of dopamine levels. The clinical presentations of autistic subjects were correlated with detected COMT variants and dopamine level. Our molecular results revealed that three COMT variants were found: rs8192488 [C > T], rs4680 (Val158Met) and rs4818 [C > G]. Within autistic subjects, Val158Met rs4680 carriers were significantly distributed (71.2% P = 0.014) accompanied with abnormal dopamine, abnormal Electroencephalogram (EEG) and increasing the severity of autistic behaviour. As regards the haplotypes, CC/VM/CG block was significantly distributed among the autistic subjects (30.8%) presented with low mean dopamine level (15.8 ± 4.7 pg/ml, p = 0.05), while CC/MM/CC were presented with high mean level (77.8 ± 8.6 pg/ml, p = 0.05). Evidence is currently limited and preliminary, further studies are necessary in order to set up a coherent dopaminergic model of Autism Spectrum Disorder (ASD), which would further pave the way for an adequate treatment.
Collapse
Affiliation(s)
- Nora N Esmaiel
- Molecular Genetics and Enzymology, Human Genetics and Genome Research Division, National Research Centre, Cairo, P.O. 12622, Egypt
| | - Engy A Ashaat
- Clinical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo, P.O. 12622, Egypt.
| | - Rehab Mosaad
- Molecular Genetics and Enzymology, Human Genetics and Genome Research Division, National Research Centre, Cairo, P.O. 12622, Egypt
| | - Alaaeldin Fayez
- Molecular Genetics and Enzymology, Human Genetics and Genome Research Division, National Research Centre, Cairo, P.O. 12622, Egypt
| | - Mona Ibrahim
- Biochemical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo, P.O. 12622, Egypt
| | - Zeinab Y Abdallah
- Biochemical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo, P.O. 12622, Egypt
| | - Mahmoud Y Issa
- Clinical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo, P.O. 12622, Egypt
| | - Sohair Salem
- Molecular Genetics and Enzymology, Human Genetics and Genome Research Division, National Research Centre, Cairo, P.O. 12622, Egypt
| | - Abeer Ramadan
- Molecular Genetics and Enzymology, Human Genetics and Genome Research Division, National Research Centre, Cairo, P.O. 12622, Egypt
| | - Maged A El Wakeel
- Child Health Department, Medical division, National Research Centre, Cairo, P.O. 12622, Egypt
| | - Neveen A Ashaat
- Faculty of Women for Science, Ain Shams University, Cairo, P.O. 11757, Egypt
| | - Maha S Zaki
- Clinical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo, P.O. 12622, Egypt
| | - Samira Ismail
- Clinical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo, P.O. 12622, Egypt
| |
Collapse
|
5
|
Ano Y, Kutsukake T, Sasaki T, Uchida S, Yamada K, Kondo K. Identification of a Novel Peptide from β-Casein That Enhances Spatial and Object Recognition Memory in Mice. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2019; 67:8160-8167. [PMID: 31241932 DOI: 10.1021/acs.jafc.9b02495] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
An increase in the aging population has spurred recent efforts to identify diet and lifestyle changes that help prevent cognitive decline. Several epidemiological investigations and clinical studies have indicated that consuming fermented dairy products prevents cognitive decline. Some peptides from whey including β-lactolin improve memory impairment; the intake of Camembert cheese has been shown to prevent Alzheimer's in mouse models. To elucidate the molecular mechanisms underlying these preventive effects, we screened peptides from digested casein protein for their ability to improve spatial memory in a scopolamine-induced amnesia mouse model. Administration of KEMPFPKYPVEP peptide from β-casein at 0.5 mg/kg (54.8 ± 2.5) and 2 mg/kg (57.9 ± 3.7) improved memory impairment in the amnesia mice in comparison with control (44.9 ± 3.4; p = 0.031 and p = 0.042, respectively) and increased dopamine (5.9 ± 3.8 [control] and 12.4 ± 6.2 [KEMPFPKYPVEP peptide]) and norepinephrine (7.7 ± 0.8 [control] and 9.9 ± 2.0 [KEMPFPKYPVEP peptide]) levels in the frontal cortex (p = 0.039 and p = 0.031, respectively). Collectively, our findings suggest that peptides in fermented dairy products prevent cognitive decline and support previously reported observations.
Collapse
Affiliation(s)
- Yasuhisa Ano
- Research Laboratories for Health Science & Food Technologies , Kirin Holdings Co. Ltd. , Yokohama , Japan
| | - Toshiko Kutsukake
- Research Laboratories for Health Science & Food Technologies , Kirin Holdings Co. Ltd. , Yokohama , Japan
| | - Toshinori Sasaki
- Research Laboratories for Health Science & Food Technologies , Kirin Holdings Co. Ltd. , Yokohama , Japan
| | - Shinichi Uchida
- Central Nervous System Research Laboratories, CNS R&D Unit, R&D Division , Kyowa Hakko Kirin Co. Ltd. , Shizuoka , Japan
| | - Koji Yamada
- Central Nervous System Research Laboratories, CNS R&D Unit, R&D Division , Kyowa Hakko Kirin Co. Ltd. , Shizuoka , Japan
| | - Keiji Kondo
- Research Laboratories for Health Science & Food Technologies , Kirin Holdings Co. Ltd. , Yokohama , Japan
| |
Collapse
|
6
|
Adem A, Madjid N, Stiedl O, Bonito-Oliva A, Konradsson-Geuken Å, Holst S, Fisone G, Ögren SO. Atypical but not typical antipsychotic drugs ameliorate phencyclidine-induced emotional memory impairments in mice. Eur Neuropsychopharmacol 2019; 29:616-628. [PMID: 30910381 DOI: 10.1016/j.euroneuro.2019.03.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Revised: 02/28/2019] [Accepted: 03/07/2019] [Indexed: 01/09/2023]
Abstract
Schizophrenia is associated with cognitive impairments related to hypofunction in glutamatergic N-methyl-D-aspartate receptor (NMDAR) transmission. Phencyclidine (PCP), a non-competitive NMDAR antagonist, models schizophrenia-like behavioral symptoms including cognitive deficits in rodents. This study examined the effects of PCP on emotional memory function examined in the passive avoidance (PA) task in mice and the ability of typical and atypical antipsychotic drugs (APDs) to rectify the PCP-mediated impairment. Pre-training administration of PCP (0.5, 1, 2 or 3 mg/kg) dose-dependently interfered with memory consolidation in the PA task. In contrast, PCP was ineffective when administered after training, and immediately before the retention test indicating that NMDAR blockade interferes with memory encoding mechanisms. The typical APD haloperidol and the dopamine D2/3 receptor antagonist raclopride failed to block the PCP-induced PA impairment suggesting a negligible role of D2 receptors in the PCP impairment. In contrast, the memory impairment was blocked by the atypical APDs clozapine and olanzapine in a dose-dependent manner while risperidone was effective only at the highest dose tested (1 mg/kg). The PCP-induced impairment involves 5-HT1A receptor mechanisms since the antagonist NAD-299 blocked the memory impairment caused by PCP and the ability of clozapine to attenuate the impairment by PCP. These results indicate that atypical but not typical APDs can ameliorate NMDAR-mediated memory impairments and support the view that atypical APDs such as clozapine can modulate glutamatergic memory dysfunctions through 5-HT1A receptor mechanisms. These findings suggest that atypical APDs may improve cognitive impairments related to glutamatergic dysfunction relevant for emotional memories in schizophrenia.
Collapse
Affiliation(s)
- Abdu Adem
- Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, United Arab Emirates.
| | - Nather Madjid
- Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, United Arab Emirates; Department of Neuroscience, Karolinska Institutet, Solnavägen 9, S-171 77 Stockholm, Sweden
| | - Oliver Stiedl
- Center for Neurogenomics and Cognitive Research, VU University Amsterdam, the Netherlands
| | | | - Åsa Konradsson-Geuken
- Department of Neuroscience, Karolinska Institutet, Solnavägen 9, S-171 77 Stockholm, Sweden
| | - Sarah Holst
- Department of Neuroscience, Karolinska Institutet, Solnavägen 9, S-171 77 Stockholm, Sweden
| | - Gilberto Fisone
- Department of Neuroscience, Karolinska Institutet, Solnavägen 9, S-171 77 Stockholm, Sweden
| | - Sven Ove Ögren
- Department of Neuroscience, Karolinska Institutet, Solnavägen 9, S-171 77 Stockholm, Sweden.
| |
Collapse
|
7
|
Ripollés P, Ferreri L, Mas-Herrero E, Alicart H, Gómez-Andrés A, Marco-Pallares J, Antonijoan RM, Noesselt T, Valle M, Riba J, Rodriguez-Fornells A. Intrinsically regulated learning is modulated by synaptic dopamine signaling. eLife 2018; 7:e38113. [PMID: 30160651 PMCID: PMC6133552 DOI: 10.7554/elife.38113] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Accepted: 08/29/2018] [Indexed: 12/13/2022] Open
Abstract
We recently provided evidence that an intrinsic reward-related signal-triggered by successful learning in absence of any external feedback-modulated the entrance of new information into long-term memory via the activation of the dopaminergic midbrain, hippocampus, and ventral striatum (the SN/VTA-Hippocampal loop; Ripollés et al., 2016). Here, we used a double-blind, within-subject randomized pharmacological intervention to test whether this learning process is indeed dopamine-dependent. A group of healthy individuals completed three behavioral sessions of a language-learning task after the intake of different pharmacological treatments: a dopaminergic precursor, a dopamine receptor antagonist or a placebo. Results show that the pharmacological intervention modulated behavioral measures of both learning and pleasantness, inducing memory benefits after 24 hr only for those participants with a high sensitivity to reward. These results provide causal evidence for a dopamine-dependent mechanism instrumental in intrinsically regulated learning and further suggest that subject-specific reward sensitivity drastically alters learning success.
Collapse
Affiliation(s)
- Pablo Ripollés
- Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute- IDIBELLL’Hospitalet de LlobregatBarcelonaSpain
- Department of Cognition, Development and Educational PsychologyCampus Bellvitge, University of Barcelona, L’Hospitalet de LlobregatBarcelonaSpain
- Department of PsychologyNew York UniversityNew YorkUnited States
| | - Laura Ferreri
- Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute- IDIBELLL’Hospitalet de LlobregatBarcelonaSpain
- Department of Cognition, Development and Educational PsychologyCampus Bellvitge, University of Barcelona, L’Hospitalet de LlobregatBarcelonaSpain
| | - Ernest Mas-Herrero
- Montreal Neurological InstituteMcGill UniversityMontrealCanada
- International Laboratory for Brain, Music, and Sound ResearchMontrealQCCanada
- Centre for Research on Brain, Language and MusicMontrealCanada
| | - Helena Alicart
- Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute- IDIBELLL’Hospitalet de LlobregatBarcelonaSpain
| | - Alba Gómez-Andrés
- Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute- IDIBELLL’Hospitalet de LlobregatBarcelonaSpain
| | - Josep Marco-Pallares
- Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute- IDIBELLL’Hospitalet de LlobregatBarcelonaSpain
- Department of Cognition, Development and Educational PsychologyCampus Bellvitge, University of Barcelona, L’Hospitalet de LlobregatBarcelonaSpain
| | - Rosa Maria Antonijoan
- Department of Pharmacology and TherapeuticsUniversitat Autònoma de BarcelonaBarcelonaSpain
- Centre d’Investigació de MedicamentsServei de Farmacologia Clínica, Hospital de la Santa Creu i Sant PauBarcelonaSpain
| | - Toemme Noesselt
- Department of NeurologyOtto-von-Guericke University, Leipziger StraßeMagdeburgGermany
- Department of Biological PsychologyOtto-von-Guericke-University Magdeburg, PostfachMagdeburgGermany
- Center for Behavioral Brain SciencesMagdeburgGermany
| | - Marta Valle
- Department of Pharmacology and TherapeuticsUniversitat Autònoma de BarcelonaBarcelonaSpain
- Pharmacokinetic/Pharmacodynamic Modeling and Simulation GroupSant Pau Institute of Biomedical ResearchBarcelonaSpain
| | - Jordi Riba
- Human Neuropsychopharmacology GroupSant Pau Institute of Biomedical ResearchBarcelonaSpain
| | - Antoni Rodriguez-Fornells
- Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute- IDIBELLL’Hospitalet de LlobregatBarcelonaSpain
- Department of Cognition, Development and Educational PsychologyCampus Bellvitge, University of Barcelona, L’Hospitalet de LlobregatBarcelonaSpain
- Catalan Institution for Research and Advanced StudiesBarcelonaSpain
| |
Collapse
|
8
|
Dopamine receptors mediate strategy abandoning via modulation of a specific prelimbic cortex-nucleus accumbens pathway in mice. Proc Natl Acad Sci U S A 2018; 115:E4890-E4899. [PMID: 29735678 DOI: 10.1073/pnas.1717106115] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
The ability to abandon old strategies and adopt new ones is essential for survival in a constantly changing environment. While previous studies suggest the importance of the prefrontal cortex and some subcortical areas in the generation of strategy-switching flexibility, the fine neural circuitry and receptor mechanisms involved are not fully understood. In this study, we showed that optogenetic excitation and inhibition of the prelimbic cortex-nucleus accumbens (NAc) pathway in the mouse respectively enhances and suppresses strategy-switching ability in a cross-modal spatial-egocentric task. This ability is dependent on an intact dopaminergic tone in the NAc, as local dopamine denervation impaired the performance of the animal in the switching of tasks. In addition, based on a brain-slice preparation obtained from Drd2-EGFP BAC transgenic mice, we demonstrated direct innervation of D2 receptor-expressing medium spiny neurons (D2-MSNs) in the NAc by prelimbic cortical neurons, which is under the regulation by presynaptic dopamine receptors. While presynaptic D1-type receptor activation enhances the glutamatergic transmission from the prelimbic cortex to D2-MSNs, D2-type receptor activation suppresses this synaptic connection. Furthermore, manipulation of this pathway by optogenetic activation or administration of a D1-type agonist or a D2-type antagonist could restore impaired task-switching flexibility in mice with local NAc dopamine depletion; this restoration is consistent with the effects of knocking down the expression of specific dopamine receptors in the pathway. Our results point to a critical role of a specific prelimbic cortex-NAc subpathway in mediating strategy abandoning, allowing the switching from one strategy to another in problem solving.
Collapse
|
9
|
Paprocki R, Lenskiy A. What Does Eye-Blink Rate Variability Dynamics Tell Us About Cognitive Performance? Front Hum Neurosci 2017; 11:620. [PMID: 29311876 PMCID: PMC5742176 DOI: 10.3389/fnhum.2017.00620] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Accepted: 12/06/2017] [Indexed: 02/03/2023] Open
Abstract
Cognitive performance is defined as the ability to utilize knowledge, attention, memory, and working memory. In this study, we briefly discuss various markers that have been proposed to predict cognitive performance. Next, we develop a novel approach to characterize cognitive performance by analyzing eye-blink rate variability dynamics. Our findings are based on a sample of 24 subjects. The subjects were given a 5-min resting period prior to a 10-min IQ test. During both stages, eye blinks were recorded from Fp1 and Fp2 electrodes. We found that scale exponents estimated for blink rate variability during rest were correlated with subjects' performance on the subsequent IQ test. This surprising phenomenon could be explained by the person to person variation in concentrations of dopamine in PFC and accumulation of GABA in the visual cortex, as both neurotransmitters play a key role in cognitive processes and affect blinking. This study demonstrates the possibility that blink rate variability dynamics at rest carry information about cognitive performance and can be employed in the assessment of cognitive abilities without taking a test.
Collapse
Affiliation(s)
- Rafal Paprocki
- Korea University of Technology and Education, Cheonan, South Korea
| | - Artem Lenskiy
- Korea University of Technology and Education, Cheonan, South Korea
| |
Collapse
|
10
|
Bezu M, Maliković J, Kristofova M, Engidawork E, Höger H, Lubec G, Korz V. Spatial Working Memory in Male Rats: Pre-Experience and Task Dependent Roles of Dopamine D1- and D2-Like Receptors. Front Behav Neurosci 2017; 11:196. [PMID: 29081740 PMCID: PMC5645514 DOI: 10.3389/fnbeh.2017.00196] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Accepted: 10/03/2017] [Indexed: 01/01/2023] Open
Abstract
The dopaminergic system is known to be involved in working memory processed by several brain regions like prefrontal cortex (PFC), hippocampus, striatum. In an earlier study we could show that Levodopa but not Modafinil enhanced working memory in a T-maze only during the early phase of training (day 3), whereas the later phase remained unaffected. Rats treated with a higher dose performed better than low dose treated rats. Here we could more specifically segregate the contributions of dopamine type 1- and 2- like receptors (D1R; D2R) to the training state dependent modulation of spatial working memory by intracerebroventricular (ICV) application of a D1R-like (SKF81297) and D2R-like agonist (Sumanirole) and antagonist (SCH23390, Remoxipride) at a low and high dose through 3 days of training. The D1R-like-agonist at both doses enhanced working memory at day 1 but only in the low dose treated rats enhancement persists over training compared to control rats. Rats treated with a high dose of a D1R-like-antagonist show persistent enhancement of working memory over training, whereas in low dose treated rats no statistical difference at any time point could be determined compared to controls. The D2R-like-agonist at both doses does not show an effect at any time point when compared to control animals, whereas the D2R-like antagonist at a low dose enhanced working memory at day 2. For the most effective D1R-like agonist, we repeated the experiments in a water maze working memory task, to test for task dependent differences in working memory modulations. Treated rats at both doses did not differ as compared to controls, but the temporal behavioral performance of all groups was different compared to T-maze trained rats. The results are in line with the view that spatial working memory is optimized within a limited range of dopaminergic transmission, however suggest that these ranges vary during spatial training.
Collapse
Affiliation(s)
- Mekite Bezu
- Department of Pediatrics, Medical University of Vienna, Vienna, Austria
| | - Jovana Maliković
- Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria
| | - Martina Kristofova
- Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria
| | - Ephrem Engidawork
- School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
| | - Harald Höger
- Core Unit of Biomedical Research, Division of Laboratory Animal Science and Genetics, Department of Biomedicine, Medical University of Vienna, Vienna, Austria
| | - Gert Lubec
- Paracelsus Medical University, Salzburg, Austria
| | - Volker Korz
- Brain Research Center, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
11
|
Repeated application of Modafinil and Levodopa reveals a drug-independent precise timing of spatial working memory modulation. Behav Brain Res 2016; 312:9-13. [DOI: 10.1016/j.bbr.2016.06.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Revised: 06/01/2016] [Accepted: 06/02/2016] [Indexed: 01/08/2023]
|
12
|
Brett ZH, Humphreys KL, Fleming AS, Kraemer GW, Drury SS. Using cross-species comparisons and a neurobiological framework to understand early social deprivation effects on behavioral development. Dev Psychopathol 2015; 27:347-67. [PMID: 25997759 PMCID: PMC5299387 DOI: 10.1017/s0954579415000036] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Building upon the transactional model of brain development, we explore the impact of early maternal deprivation on neural development and plasticity in three neural systems: hyperactivity/impulsivity, executive function, and hypothalamic-pituitary-adrenal axis functioning across rodent, nonhuman primate, and human studies. Recognizing the complexity of early maternal-infant interactions, we limit our cross-species comparisons to data from rodent models of artificial rearing, nonhuman primate studies of peer rearing, and the relations between these two experimental approaches and human studies of children exposed to the early severe psychosocial deprivation associated with institutional care. In addition to discussing the strengths and limitations of these paradigms, we present the current state of research on the neurobiological impact of early maternal deprivation and the evidence of sensitive periods, noting methodological challenges. Integrating data across preclinical animal models and human studies, we speculate about the underlying biological mechanisms; the differential impact of deprivation due to temporal factors including onset, offset, and duration of the exposure; and the possibility and consequences of reopening of sensitive periods during adolescence.
Collapse
|
13
|
Brett ZH, Sheridan M, Humphreys K, Smyke A, Gleason MM, Fox N, Zeanah C, Nelson C, Drury S. A neurogenetics approach to defining differential susceptibility to institutional care. INTERNATIONAL JOURNAL OF BEHAVIORAL DEVELOPMENT 2015; 39:150-160. [PMID: 25663728 PMCID: PMC4317330 DOI: 10.1177/0165025414538557] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
An individual's neurodevelopmental and cognitive sequelae to negative early experiences may, in part, be explained by genetic susceptibility. We examined whether extreme differences in the early caregiving environment, defined as exposure to severe psychosocial deprivation associated with institutional care compared to normative rearing, interacted with a biologically informed genoset comprising BDNF (rs6265), COMT (rs4680), and SIRT1 (rs3758391) to predict distinct outcomes of neurodevelopment at age 8 (N = 193, 97 males and 96 females). Ethnicity was categorized as Romanian (71%), Roma (21%), unknown (7%), or other (1%). We identified a significant interaction between early caregiving environment (i.e., institutionalized versus never institutionalized children) and the a priori defined genoset for full-scale IQ, two spatial working memory tasks, and prefrontal cortex gray matter volume. Model validation was performed using a bootstrap resampling procedure. Although we hypothesized that the effect of this genoset would operate in a manner consistent with differential susceptibility, our results demonstrate a complex interaction where vantage susceptibility, diathesis stress, and differential susceptibility are implicated.
Collapse
Affiliation(s)
| | | | | | - Anna Smyke
- Tulane University School of Medicine, USA
| | | | | | | | - Charles Nelson
- Boston Children's Hospital and Harvard Medical School, USA
| | | |
Collapse
|
14
|
Xu ZH, Yang Q, Feng B, Liu SB, Zhang N, Xing JH, Li XQ, Wu YM, Gao GD, Zhao MG. Group I mGluR antagonist rescues the deficit of D1-induced LTP in a mouse model of fragile X syndrome. Mol Neurodegener 2012; 7:24. [PMID: 22640474 PMCID: PMC3467183 DOI: 10.1186/1750-1326-7-24] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2011] [Accepted: 04/17/2012] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Fragile X syndrome (FXS) is caused by the absence of the mRNA-binding protein Fragile X mental retardation protein (FMRP), encoded by the Fmr1 gene. Overactive signaling by group 1 metabotropic glutamate receptor (Grp1 mGluR) could contribute to slowed synaptic development and other symptoms of FXS. Our previous study has identified that facilitation of synaptic long-term potentiation (LTP) by D1 receptor is impaired in Fmr1 knockout (KO) mice. However, the contribution of Grp1 mGluR to the facilitation of synaptic plasticity by D1 receptor stimulation in the prefrontal cortex has been less extensively studied. RESULTS Here we demonstrated that DL-AP3, a Grp1 mGluR antagonist, rescued LTP facilitation by D1 receptor agonist SKF81297 in Fmr1KO mice. Grp1 mGluR inhibition restored the GluR1-subtype AMPA receptors surface insertion by D1 activation in the cultured Fmr1KO neurons. Simultaneous treatment of Grp1 mGluR antagonist with D1 agonist recovered the D1 receptor signaling by reversing the subcellular redistribution of G protein-coupled receptor kinase 2 (GRK2) in the Fmr1KO neurons. Treatment of SKF81297 alone failed to increase the phosphorylation of NR2B-containing N-methyl D-aspartate receptors (NMDARs) at Tyr-1472 (p-NR2B-Tyr1472) in the cultures from KO mice. However, simultaneous treatment of DL-AP3 could rescue the level of p-NR2B-Tyr1472 by SKF81297 in the cultures from KO mice. Furthermore, behavioral tests indicated that simultaneous treatment of Grp1 mGluR antagonist with D1 agonist inhibited hyperactivity and improved the learning ability in the Fmr1KO mice. CONCLUSION The findings demonstrate that mGluR1 inhibition is a useful strategy to recover D1 receptor signaling in the Fmr1KO mice, and combination of Grp1 mGluR antagonist and D1 agonist is a potential drug therapy for the FXS.
Collapse
Affiliation(s)
- Zhao-Hui Xu
- Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, 17 Changle West Road, Xi'an, 710032, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Fatemi SH, Folsom TD. Dysregulation of fragile × mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study. Mol Autism 2011; 2:6. [PMID: 21548960 PMCID: PMC3488976 DOI: 10.1186/2040-2392-2-6] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2010] [Accepted: 05/06/2011] [Indexed: 12/26/2022] Open
Abstract
Background Fragile X syndrome is caused by loss of function of the fragile X mental retardation 1 (FMR1) gene and shares multiple phenotypes with autism. We have previously found reduced expression of the protein product of FMR1 (FMRP) in vermis of adults with autism. Methods In the current study, we have investigated levels of FMRP in the superior frontal cortex of people with autism and matched controls using Western blot analysis. Because FMRP regulates the translation of multiple genes, we also measured protein levels for downstream molecules metabotropic glutamate receptor 5 (mGluR5) and γ-aminobutyric acid (GABA) A receptor β3 (GABRβ3), as well as glial fibrillary acidic protein (GFAP). Results We observed significantly reduced levels of protein for FMRP in adults with autism, significantly increased levels of protein for mGluR5 in children with autism and significantly increased levels of GFAP in adults and children with autism. We found no change in expression of GABRβ3. Our results for FMRP, mGluR5 and GFAP confirm our previous work in the cerebellar vermis of people with autism. Conclusion These changes may be responsible for cognitive deficits and seizure disorder in people with autism.
Collapse
Affiliation(s)
- S Hossein Fatemi
- Division of Neuroscience Research, Department of Psychiatry, University of Minnesota Medical School, 420 Delaware Street SE, MMC 392, Minneapolis, MN 55455, USA.
| | | |
Collapse
|
16
|
Podda MV, Riccardi E, D'Ascenzo M, Azzena GB, Grassi C. Dopamine D1-like receptor activation depolarizes medium spiny neurons of the mouse nucleus accumbens by inhibiting inwardly rectifying K+ currents through a cAMP-dependent protein kinase A-independent mechanism. Neuroscience 2010; 167:678-90. [PMID: 20211700 DOI: 10.1016/j.neuroscience.2010.02.075] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2009] [Revised: 02/06/2010] [Accepted: 02/28/2010] [Indexed: 01/15/2023]
Abstract
Dopamine/cAMP signaling has been reported to mediate behavioral responses related to drug addiction. It also modulates the plasticity and firing properties of medium spiny neurons (MSNs) in the nucleus accumbens (NAc), although the effects of cAMP signaling on the resting membrane potential (RMP) of MSNs has not been specifically defined. In this study, activation of dopamine D1-like receptors (D1Rs) by SKF-38393 elicited membrane depolarization and inward currents in MSNs from the NAc core of 14-17 day-old mice. Similar results were obtained following stimulation of adenylyl cyclase (AC) activity with forskolin or application of exogenous cAMP. Forskolin occluded SKF-38393's effects, thus indicating that D1R action is mediated by AC/cAMP signaling. Accordingly, AC blockade by SQ22536 significantly inhibited the responses to SKF-38393. Effects elicited by D1R stimulation or increased cAMP levels were unaffected by protein kinase A (PKA) or protein kinase C (PKC) blockade and were not mimicked by the Epac agonist, 8CPT-2Me-cAMP. Responses to forskolin were also not significantly modified by cyclic nucleotide-gated (CNG) channel blockade. Forskolin-induced membrane depolarization was associated with increased membrane input resistance. Voltage-clamp experiments revealed that forskolin and SKF-38393 effects were due to inhibition of resting K(+) currents exhibiting inward rectification at hyperpolarized potentials and a reversal potential (around -90 mV) that shifted with the extracellular K(+) concentration. Forskolin and D1R agonist effects were abolished by the inward rectifier K(+) (Kir)-channel blocker, BaCl(2). Collectively, these data suggest that stimulation of postsynaptic D1Rs in MSNs of the NAc core causes membrane depolarization by inhibiting Kir currents. This effect is mediated by AC/cAMP signaling but it is independent on PKA, PKC, Epac and CNG channel activation, suggesting that it may stem from cAMP's direct interaction with Kir channels. D1R/cAMP-mediated excitatory effects may influence the generation of output signals from MSNs by facilitating their transition from the quiescent down-state to the functionally active up-state.
Collapse
Affiliation(s)
- M V Podda
- Institute of Human Physiology, Medical School, Catholic University S. Cuore, Rome, Italy
| | | | | | | | | |
Collapse
|
17
|
Potential pharmacological treatment of fragile X syndrome during adulthood. Neurosci Bull 2009; 25:296-300. [PMID: 19784085 DOI: 10.1007/s12264-009-0909-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
Fragile X syndrome (FXS) is the most common form of inherited mental retardation, characterized by moderate-to-severe mental retardation, attention deficits, and hyperactivity. This disease results from the expansion of a trinucleotide repeat (CGG) within the X-linked fragile X mental retardation 1 (FMR1) gene, which leads to the lack of the product of the FMR1 gene-fragile X mental retardation protein. Many mental disorders such as FXS and Rett syndrome are thought to originate during early developmental period, but recent findings have suggested the involvement of the processes in the adult nervous system. Here we outline our recent studies and initial clinical trials that may provide an approach to treat FXS in the adulthood.
Collapse
|
18
|
Wang H, Wu LJ, Kim SS, Lee FJS, Gong B, Toyoda H, Ren M, Shang YZ, Xu H, Liu F, Zhao MG, Zhuo M. FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron 2008; 59:634-47. [PMID: 18760699 DOI: 10.1016/j.neuron.2008.06.027] [Citation(s) in RCA: 153] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2007] [Revised: 03/14/2008] [Accepted: 06/13/2008] [Indexed: 11/17/2022]
Abstract
The fragile X mental retardation protein (FMRP) is an RNA-binding protein that controls translational efficiency and regulates synaptic plasticity. Here, we report that FMRP is involved in dopamine (DA) modulation of synaptic potentiation. AMPA glutamate receptor subtype 1 (GluR1) surface expression and phosphorylation in response to D1 receptor stimulation were reduced in cultured Fmr1(-/-) prefrontal cortex (PFC) neurons. Furthermore, D1 receptor signaling was impaired, accompanied by D1 receptor hyperphosphorylation at serine sites and subcellular redistribution of G protein-coupled receptor kinase 2 (GRK2) in both PFC and striatum of Fmr1(-/-) mice. FMRP interacted with GRK2, and pharmacological inhibition of GRK2 rescued D1 receptor signaling in Fmr1(-/-) neurons. Finally, D1 receptor agonist partially rescued hyperactivity and enhanced the motor function of Fmr1(-/-) mice. Our study has identified FMRP as a key messenger for DA modulation in the forebrain and may provide insights into the cellular and molecular mechanisms underlying fragile X syndrome.
Collapse
Affiliation(s)
- Hansen Wang
- Department of Physiology, Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S1A8, Canada
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|